

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Daniela Matuozzo^{1,2}, Estelle Talouarn^{1,2}, Astrid Marchal^{1,2}, Jeremy Manry^{1,2}, Yoann Seeleuthner^{1,2}, Yu Zhang³, Alexandre Bolze⁴, Matthieu Chaldebas⁵, Baptiste Milisavljevic⁵, Peng Zhang⁵, Adrian Gervais^{1,2}, Paul Bastard^{1,2,5}, Takaki Asano⁵, Lucy Bizien^{1,2}, Federica Barzaghi⁶, Hassan Abolhassani^{7,8}, Ahmad Abou Tayoun^{9,10}, Alessandro Aiuti^{11,12}, Ilad Alavi Darazam^{13,14}, Luis M. Allende¹⁵, Rebeca Alonso-Arias¹⁶, Andrés Augusto Arias^{5,17,18}, Gokhan Aytekin¹⁹, Peter Bergman^{20,21}, Simone Bondesan²², Yenan T. Bryceson²³, Ingrid G. Bustos²⁴, Oscar Cabrera-Marante²⁵, Sheila Carcel²⁶, Paola Carrera²², Giorgio Casari^{27,28}, Khalil Chaïbi^{29,30}, Roger Colobran^{31,32,33}, Antonio Condino-Neto³⁴, Laura E. Covill²³, Loubna El Zein³⁵, Carlos Flores^{36,37,38,39}, Peter K. Gregersen⁴⁰, Marta Gut⁴¹, Filomeen Haerynck⁴², Rabih Halwani⁴³, Selda Hancerli⁴⁴, Lennart Hammarström⁷, Nevin Hatipoğlu⁴⁵, Adem Karbuz⁴⁶, Sevgi Keles⁴⁷, Christèle Kyheng⁴⁸, Rafael Leon-Lopez²⁶, Jose Luis Franco⁴⁹, Davood Mansouri^{50,51,52}, Javier Martinez-Picado^{53,54,55,56,57}, Ozge Metin Akcan⁴⁷, Isabelle Migeotte⁵⁸, Pierre-Emmanuel Morange^{59,60}, Guillaume Morelle⁴⁸, Andrea Martin-Nalda^{31,61,62}, Giuseppe Novelli^{63,64}, Antonio Novelli⁶⁵, Tayfun Ozcelik⁶⁶, Figen Palabiyik⁴⁵, Qiang Pan-Hammarström⁷, Rebeca Pérez de Diego⁶⁷, Laura Planas-Serra^{68,69}, Daniel E. Pleguezuelo¹⁵, Carolina Prando⁷⁰, Aurora Pujol^{56,68,69}, Luis Felipe Reyes⁷¹, Jacques G. Rivière^{31,61,62}, Carlos Rodriguez-Gallego^{72,73}, Julian Rojas⁴⁹, Patrizia Rovere-Querini^{12,74}, Agatha Schlüter^{68,69}, Mohammad Shahrooei^{75,76}, Ali Sobh⁷⁷, Pere Soler-Palacin^{31,61,62}, Yacine Tandjaoui-Lambiotte⁷⁸, Imran Tipu⁷⁹, Cristina Tresoldi⁸⁰, Jesus Troya⁸¹, Diederik van de Beek⁸², Mayana Zatz⁸³, Pawel Zawadzki^{84,85}, Saleh Zaid Al-Muhsen⁸⁶, Hagit Baris-Feldman^{87,88}, Manish J. Butte⁸⁹, Stefan N. Constantinescu^{90,91,92,93}, Megan A. Cooper⁹⁴, Clifton L. Dalgard^{95,96}, Jacques

Fellay^{97,98,99}, James R. Heath¹⁰⁰, Yu-Lung Lau¹⁰¹, Richard P. Lifton^{102,103,104}, Tom Maniatis^{105,106}, Trine H. Mogensen^{107,108}, Horst von Bernuth¹⁰⁹, Alban Lermine¹¹⁰, Michel Vidaud¹¹⁰, Anne Boland¹¹¹, Jean-François Deleuze¹¹¹, Robert Nussbaum¹¹², Amanda Kahn-Kirby¹¹², France Mentre¹¹³, Sarah Tubiana¹¹⁴, Guy Gorochov¹¹⁵, Florence Tubach¹¹⁶, Pierre Hausfater^{117,118}, COVID Human Genetic Effort, COVDeF Study Group, French COVID Cohort Study Group, CoV-Contact Cohort, COVID-STORM Clinicians, COVID Clinicians, Orchestra Working Group, Amsterdam UMC Covid-19 Biobank, NIAID-USUHS COVID Study Group, Isabelle Meyts¹¹⁹, Shen-Ying Zhang^{1,2,5}, Anne Puel^{1,2,5}, Luigi D. Notarangelo¹²⁰, Stephanie Boisson-Dupuis^{1,2,5}, Helen C. Su³, Bertrand Boisson^{1,2,5}, Emmanuelle Jouanguy^{1,2,5}, Jean-Laurent Casanova^{1,2,5,121,*}, Qian Zhang^{1,2,5,*}, Laurent Abel^{1,2,5,*}, Aurélie Cobat^{1,2,5,*}

¹Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Paris, France

²University Paris Cité, Imagine Institute, Paris, France

³Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, Bethesda, MD, USA

⁴Helix, San Mateo, CA, USA

⁵St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA

⁶Department of Paediatric Immunohematology, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁷Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden

⁸Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran, Iran

⁹Al Jalila Genomics Center of Excellence, Al Jalila Children's Specialty Hospital, Dubai,

United Arab Emirates

¹⁰Center for Genomic Discovery, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates

¹¹San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCSS San Raffaele Scientific Institute, Milan, Italy

¹²Vita-Salute San Raffaele University, Milan, Italy

¹³Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

¹⁴Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

¹⁵Immunology Department, University Hospital 12 de Octubre, Research Institute IMA12 and Complutense University, Madrid, Spain

¹⁶Immunology Department, Hospital Universitario Central de Asturias, Oviedo, Spain

¹⁷Primary Immunodeficiencies Group, Department of Microbiology and Parasitology, School of Medicine, University of Antioquia UdeA, 050010 Medellin, Colombia

¹⁸School of Microbiology, University of Antioquia UdeA, 050010 Medellin, Colombia

¹⁹Department of Internal Medicine, Division of Allergy and Immunology, Konya City Hospital, Konya, Turkey

²⁰Department of Infectious Diseases, The Immunodeficiency Unit, Karolinska University Hospital, Stockholm, Sweden

²¹Department of Laboratory Medicine, Division of Clinical Microbiology, Division of Clinical Microbiology, Stockholm, Sweden

²²Clinical Genomics, IRCSS San Raffaele Scientific Institute, Milan, Italy

²³Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska

Institute, Stockholm, Sweden

²⁴Universidad de La Sabana, Chía, Colombia

²⁵Institute of Biomedical Research of IdiPAZ, University Hospital “La Paz”, Madrid, Spain

²⁶Unidad de Gestión Clínica de Cuidados Intensivos, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba (UCO), Córdoba, Spain

²⁷Genome-Phenome Relationship, Division of Genetics and Cell Biology, San Raffaele Hospital, Milan, Italy

²⁸Vita-Salute San Raffaele University, School of Medicine, Milan, Italy

²⁹Anesthesiology and Critical Care Medicine Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France

³⁰Common and Rare Kidney Diseases, Sorbonne University, INSERM UMR-S 1155, Paris, France

³¹Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain

³²Translational Immunology Research Group, Vall d’Hebron Research Institute (VHIR), Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain

³³Immunology Division, Genetics Department, Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Barcelona Hospital Campus, Autonomous University of Barcelona (UAB), Barcelona, Catalonia, Spain

³⁴Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

³⁵Biology Department, Lebanese University, Beirut, Lebanon

³⁶Genomics Division, Institute of Technology and Renewable Energies (ITER), Santa Cruz de Tenerife, Spain

³⁷CIBER de Enfermedades Respiratorias, Carlos III Health Institute, Madrid, Spain

³⁸Research Unit, University Hospital of Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain

³⁹Faculty of Health Sciences, University of Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain

⁴⁰Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY, USA

⁴¹CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

⁴²Primary Immune Deficiency Research Laboratory, Department of Internal Diseases and Pediatrics, Centre for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Centre, Ghent, Belgium

⁴³Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates

⁴⁴Department of Pediatrics (Infectious Diseases), Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

⁴⁵Pediatric Infectious Diseases Unit, Bakirkoy Dr Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

⁴⁶Department of Pediatric Infectious Disease, Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey

⁴⁷Necmettin Erbakan University, Meram Medical Faculty, Division of Pediatric Allergy and Immunology, Konya, Turkey

⁴⁸Department of General Paediatrics, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris,

University of Paris Saclay, Le Kremlin-Bicêtre, France

⁴⁹Primary Immunodeficiencies Group, School of Microbiology, University of Antioquia

UdeA, Medellín, Colombia

⁵⁰The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁵¹Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁵²Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁵³IrsiCaixa AIDS Research Institute and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain

⁵⁴Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain

⁵⁵Department of Infectious Diseases and Immunity, University of Vic-Central University of Catalonia, Vic, Spain

⁵⁶Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain

⁵⁷Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain

⁵⁸Centre de Génétique Humaine de l'Université Libre de Bruxelles, Hôpital Erasme, Brussels, Belgium

⁵⁹Laboratory of Haematology, La Timone Hospital, Marseille, France

⁶⁰C2VN, INSERM, INRAE, Aix-Marseille University, Marseille, France

⁶¹Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Research

Institute (VHIR), Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus, Autonomous University of Barcelona (UAB), Barcelona, Catalonia, Spain

⁶²Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain

⁶³Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy

⁶⁴IRCCS Neuromed, Pozzilli, Italy, Italy

⁶⁵Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy

⁶⁶Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey

⁶⁷Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, University Hospital "La Paz", Madrid, Spain

⁶⁸Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain

⁶⁹Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain

⁷⁰Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Brazil

⁷¹University of La Sabana, Chía, Colombia

⁷²Department of Immunology, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria, Spain

⁷³Department of Clinical Sciences, University of Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain

⁷⁴Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁷⁵Specialized Immunology Laboratory of Dr Shahrooei, Sina Medical Complex, Ahvaz, Iran

⁷⁶Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium

⁷⁷Department of Pediatrics, Mansoura University Children's Hospital, Mansoura University Faculty of Medicine, Mansoura, Egypt

⁷⁸Hypoxia and Lung, INSERM U1272, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Bobigny, France

⁷⁹Department of Life sciences, School of Science, University of Management and Technology, Lahore, Pakistan

⁸⁰Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy

⁸¹Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain

⁸²Amsterdam UMC, Department of Neurology, Amsterdam Neuroscience, Amsterdam, Netherlands

⁸³Biosciences Institute, University of São Paulo, São Paulo, Brazil

⁸⁴MNM Bioscience Inc., Cambridge, MA, USA

⁸⁵Faculty of Physics, Adam Mickiewicz University, Poznan, Poland

⁸⁶Immunology Research laboratory, Department of Pediatrics, College of Medicine and King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia

⁸⁷The Genetics Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

⁸⁸Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

⁸⁹Departments of Pediatrics and Microbiology, Immunology, and Molecular Genetics, Division of Immunology, Allergy, and Rheumatology, University of California Los Angeles, Los Angeles, California, USA

⁹⁰Ludwig Institute for Cancer Research, Brussels, Belgium

⁹¹SIGN Unit, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium

⁹²WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Brussels, Belgium

⁹³Ludwig Institute for Cancer Research, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom

⁹⁴Department of Pediatrics, Division of Rheumatology/Immunology, Washington University in St. Louis, St. Louis, MO, USA

⁹⁵The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda

⁹⁶Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

⁹⁷School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

⁹⁸Swiss Institute of Bioinformatics, Lausanne, Switzerland

⁹⁹Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

¹⁰⁰Institute for Systems Biology, Seattle, WA, USA

¹⁰¹Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China

¹⁰²Laboratory of Genetics and Genomics, The Rockefeller University, New York, NY, USA

¹⁰³Department of Genetics, Yale University School of Medicine, New Haven, CT, USA

¹⁰⁴Yale Center for Genome Analysis, Yale School of Medicine, New Haven, CT, USA

¹⁰⁵Zukerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

¹⁰⁶New York Genome Center, New York, NY, USA

¹⁰⁷Department of Biomedicine, Aarhus University, Aarhus, Denmark

¹⁰⁸Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark

¹⁰⁹Department of Paediatric Respiratory Medicine, Immunology, and Critical Care Medicine,
Charité Universitätsmedizin Berlin, Berlin, Germany

¹¹⁰FMG2025, FMG2025, Laboratoire de biologie médicale multisites Sequoia, Paris, France

¹¹¹Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine
(CNRGH), Evry, France

¹¹²Invitae, San Francisco, CA, USA

¹¹³Unité de recherche clinique, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris,
France

¹¹⁴Centre d'Investigation Clinique, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris,
Paris, France

¹¹⁵Département d'immunologie, INSERM Centre d'Immunologie Et Des Maladies
Infectieuses CIMI-Paris, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris,
Sorbonne Université, Paris, France

¹¹⁶Département de Santé Publique, Unité de Recherche Clinique PSL-CFX, CIC-1901, Institut
Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Hôpital Pitié-Salpêtrière,
Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France

¹¹⁷Emergency Department, Hôpital Pitié-Salpêtrière, APHP-Sorbonne Université, Paris,
France

¹¹⁸GRC-14 BIOFAST Sorbonn Université, UMR INSERM 1166, IHU ICAN, Sorbonne
Université, Paris, France

¹¹⁹Laboratory for Inborn Errors of Immunity, Department of Microbiology, Immunology and
Transplantation, KU Leuven, Leuven, Belgium

¹²⁰Laboratory of Host Defenses, NIAID, National Institutes of Health, Bethesda, MA, USA

¹²¹Howard Hughes Medical Institute, New York, NY, USA

* These authors contributed equally to this work.

Corresponding authors: Aurélie Cobat (aurelie.cobat@inserm.fr) and Jean-Laurent Casanova (casanova@rockefeller.edu)

Abstract

Background

We previously reported inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity in 1-5% of unvaccinated patients with life-threatening COVID-19, and auto-antibodies against type I IFN in another 15-20% of cases.

Methods

We report here a genome-wide rare variant burden association analysis in 3,269 unvaccinated patients with life-threatening COVID-19 (1,301 previously reported and 1,968 new patients), and 1,373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. A quarter of the patients tested had antibodies against type I IFN (234 of 928) and were excluded from the analysis.

Results

No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was *TLR7*, with an OR of 27.68 (95%CI:1.5-528.7, $P=1.1\times 10^{-4}$), in analyses restricted to biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR=3.70 [95%CI:1.3-8.2], $P=2.1\times 10^{-4}$). Adding the recently reported *TYK2* COVID-19 locus strengthened this enrichment, particularly under a recessive model (OR=19.65 [95%CI:2.1-2635.4]; $P=3.4\times 10^{-3}$). When these 14 loci and *TLR7* were considered, all individuals hemizygous ($n=20$) or homozygous ($n=5$) for pLOF or bLOF variants were patients (OR=39.19 [95%CI:5.2-5037.0], $P=4.7\times 10^{-7}$), who also showed an enrichment in heterozygous variants (OR=2.36 [95%CI:1.0-5.9], $P=0.02$). Finally, the patients

with pLOF or bLOF variants at these 15 loci were significantly younger (mean age [SD]=43.3 [20.3] years) than the other patients (56.0 [17.3] years; $P=1.68 \times 10^{-5}$).

Conclusions

Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old.

Keywords

Rare variants, COVID-19, Immunity, Type I Interferon

Background

Clinical variability is high in unvaccinated individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to lethal disease. In ~3% of cases, infection leads to critical COVID-19 pneumonia, requiring high-flow oxygen ($O_2 > 6$ L/min), mechanical ventilation (non-invasive or by intubation), or extracorporeal membrane oxygenation (ECMO) [1]. Advanced age is by far the strongest predictor of COVID-19 severity, with the risk of death doubling every five years of age from childhood onward [2,3]. Men are also at greater risk of death than women [3–5]. Genome-wide (GW) association studies have identified several common loci associated with COVID-19 severity, the most significant being a region on chromosome 3p21.31 that was introduced by archaic introgression from Neanderthals [6–10]. The risk haplotype encompasses six genes and confers an estimated OR per copy of between 1.6 and 2.1, with higher values for individuals under 60 years old [7,11]. Twenty-four GW regions have been shown to be significantly associated with critical COVID-19 [10–12]. Four of these regions encompass genes involved in type I IFN immunity. The first, on chr12q24.13, containing protective variants, is also a Neanderthal haplotype and includes the *OAS1*, *OAS2*, and *OAS3* cluster, which are interferon stimulated genes (ISGs) required for the activation of antiviral RNaseL [13]. The second, a region on chr21q22.1, includes *IFNAR2*. The third, a region on chr19p13.2, includes *TYK2*. The fourth, a region on chr9p21, includes *IFNA10*. However, common variants have a modest effect size and explain only a very small fraction of the clinical variability [6,8]. This prompted us to search for rare variants conferring a stronger predisposition to life-threatening COVID-19.

Through a candidate approach focusing on influenza susceptibility genes, the COVID Human Genetics Effort (CHGE, www.covindhge.com) provided proof-of-concept that

autosomal inborn errors of TLR3-dependent and -independent type I interferon (IFN) immunity, including autosomal recessive (AR) deficiencies of IFNAR1 or IRF7, can underlie critical COVID-19 [14]. Other children with AR IFNAR1, IFNAR2, TBK1, or STAT2 deficiency were subsequently reported, as well as children with AR TYK2 deficiency [15–19] (Figure 1). Some other groups were unable to replicate these findings, but the variants were not tested biochemically and it is unclear whether recessive defects were considered [11,20–22]. There may also be other reasons for their findings [1,23], the most important being the age distribution of the case cohorts. The other case cohorts were much older than ours (mean age of 66 vs. 52 years) and we found that inborn errors of immunity (IEI) were more frequent in patients under 60 years old. Consistently, we recently reported that ~10% of children with moderate, severe, or critical COVID-19 pneumonia had recessive inborn errors of type I IFN immunity [18]. Moreover, older patients are more likely to carry pre-existing autoantibodies (auto-Abs) neutralizing type I IFN, which are found in about 15% of critical cases and up to 21% of patients over the age of 80 years [24,25]. The presence of such auto-Abs has been replicated by at least 26 studies worldwide [26,27], and we also recently showed that autoimmunity to type I IFNs is a strong common predictor of COVID-19 death in unvaccinated individuals, providing further evidence for the role of type I IFN immunity in life-threatening COVID-19.

Using an unbiased X-wide gene burden test, we also identified X-linked recessive (XR) TLR7 deficiency in 17 male patients aged 7-71 years with critical COVID-19 pneumonia, accounting for ~1% of cases in men (Figure 1) [28]. Moreover, six of the 11 *TLR7* variants previously reported in patients from other studies were deleterious (carried by nine of 16 patients) [29–34], whereas the *TLR7* variants in other studies were not disclosed [20,21]. TLR3 senses viral dsRNA in respiratory epithelial cells, whereas TLR7 senses ssRNA in plasmacytoid

dendritic cells [1]. Both pathways induce the production of type I IFNs. *TLR7* gain-of-function variants were recently shown to be associated with human systemic lupus erythematosus [35], providing an example of mirror genetic effects between infectious and inflammatory/autoimmune diseases [36]. Collectively, these findings suggest that type I IFNs are essential for protective immunity to SARS-CoV-2 in the respiratory tract, with insufficient type I IFN activity accounting for up to 15-20% of cases of life-threatening COVID-19. Despite this high proportion, the determinants of critical COVID-19 pneumonia remain to be identified in ~80% of cases. Here, we tested the hypotheses that other IEI may underlie critical COVID-19 pneumonia in at least some patients, and that our initial findings could be replicated in a new cohort. With the CHGE, we performed a GW gene-based rare variant association analysis. This analysis was performed in both previously investigated patients who had not been screened at the GW level [14,18,28], and in newly recruited patients.

Materials and Methods

Cohort

Since the beginning of the pandemic, we have enrolled more than 9,000 individuals with SARS-CoV2 infection and broad clinical manifestations from all over the world through the COVID Human Genetic Effort (CHGE). In this study we focused on patients with life-threatening COVID-19 and asymptomatic/mild infection. Life-threatening COVID-19 cases are defined as patients with pneumonia who developed critical disease, whether pulmonary with high-flow oxygen (>6 liter/min) or mechanical ventilation [continuous positive airway pressure (CPAP), bilevel positive airway pressure (BIPAP), and intubation], septic shock, or any other type of organ damage requiring intensive care unit admission (N=3503). We screened for the presence

of autoantibodies (auto-Abs) against type I IFNs all patients for whom plasma was available (N=928) as previously described [24,25]. We excluded from the present analysis 234 patients who tested positive for auto-Abs as they already have a major risk factor for developing critical COVID-19 [27]. Controls are defined as individuals infected with SARS-CoV-2 who remained asymptomatic or pauci-symptomatic, with the presence of mild, self-healing, ambulatory disease (N=1373). Presence of infection has been assessed based on a positive PCR test and/or serological test and/or the presence of typical symptoms such as anosmia or ageusia after exposure to a confirmed COVID-19 case. Cases and controls were whole-exome (N= 2003 cases and 866 controls) or whole-genome (N=1266 cases and 507 controls) sequenced and high quality variants were obtained from the sequencing data as detailed in the Supplementary Methods.

Population stratification

Principal component analysis (PCA) was performed with PLINK v1.9 software [37] on a pruned subset of ~14,600 SNPs in linkage equilibrium (maximum r^2 value of linkage disequilibrium 0.4 between pairs of SNPs) with minor allele frequency (MAF) > 1% , call rate > 99% and P value for departure from Hardy-Weinberg equilibrium > 10^{-5} as previously performed [38]. Ethnic origin was inferred from the PCA as previously described [38].

Variant selection

For each gene, we considered several sets of candidate coding variants, defined according to (i) the functional annotation: predicted loss-of-function (pLOF) variants only (including stop

gain/lost, start lost, frameshift, or splice variants), or pLOF with missense and inframe variants (MISSLOF); (ii) the Gnomad v2.1 allele frequency: variants with a Gnomad allele frequency below 1%, 0,1%, or 0,01%; and (iii) the CADD score for missense and inframe variants: missense and inframe variants with CADD score \geq MSC for the corresponding gene or all the variants regardless of the CADD score.

Rare variants burden analysis

We performed a genome-wide gene-based rare variants burden analysis. For each gene, the genotypic information at the candidate rare variants was summarized into a genetic score defined according to three genetic models: (i) co-dominant: samples are coded 2 if they carry at least one homozygous variant, 1 if they carry at least one heterozygous variant and 0 otherwise; (2) heterozygous: samples are coded 1 if they carry at least one heterozygous variant and 0 otherwise; and (3) recessive: samples are coded 1 if they carry at least one homozygous variant and 0 otherwise. For the X chromosome, hemizygous males are considered as homozygous females. Association between the genetic score for each gene and the disease status was tested by means of logistic regression-based likelihood ratio test (LRT) using EPACTS (Efficient and Parallelizable Association Container Toolbox) (<http://genome.sph.umich.edu/wiki/EPACTS>) for the genome-wide burden analysis or R 3.6.0 (<https://cran.r-project.org/>) for the candidate type I IFN related pathway. Firth's bias correction, using the fast.logistf.fit function of EPACTS or the logistf function of the R logistf package, was applied if the *P value* of the LRT was below 0.05. Analyses were adjusted on sex, age (in years) and five first PCs of the PCA. In Firth's regression, a penalty term is placed on the standard maximum likelihood function used to estimate parameters of a logistic regression

model when there are rare events or when complete separation exists [39]. With no covariates, this corresponds to adding 0.5 in every cell of a 2 by 2 table of allele counts versus case-control status. For a given gene and variant set, the burden test was not performed if the number of carriers across all samples was lower than 3.

We used three analysis strategies: 1) joint analysis of all samples; 2) trans-ethnic meta-analysis: the analysis was stratified according to 7 inferred ancestry subgroups (African, North African, European, admixed American, Middle Eastern, South Asian, East Asian). For each subgroup, an ethnic specific PCA was computed and used in the logistic regression model; and 3) trans-pipeline meta-analysis to account for the heterogeneity due to the type of sequencing data: the analysis was stratified according to the type of data shared (FASTQ vs VCF). Subgroups P values were further meta-analyzed accounting for the direction of effect and sample size using METAL [40].

Multiple testing correction

For each gene, up to 18 burden tests were performed. Because these tests were not independent, we assessed the effective number of burden tests M_{eff} by a method adapted from Patin et al. [41], based on the approach of Li and Ji [42]. This approach makes use of the variance of the eigenvalues of the observed statistics correlation matrix to estimate M_{eff} . The Bonferroni corrected threshold was then defined as $0.05/M_{eff}$.

Odds ratio (OR) equality for homozygous/hemizygous versus heterozygous carriers of pLOF variants at type I IFN genes

We tested whether the odd of critical COVID-19 for carriers versus non-carriers of pLOF variants at the type I IFN differed according to the zygosity status (homozygous/hemizygous vs heterozygous). In the full sample, we compared using LRT a full Firth bias corrected logistic regression model including two different parameters for carriers of pLOF according to the zygosity status (alternative hypothesis) with a Firth bias corrected logistic regression model including only one parameter for carriers of pLOF regardless of the zygosity status (null hypothesis). Analysis was performed with the R `logistf` package.

Results

Cohort description

Through the CHGE, we collected whole-exome sequencing (WES) or whole-genome sequencing (WGS) data for 3,503 patients with life-threatening COVID-19 pneumonia (hereafter referred to as “patients”; see Supplemental Methods) and 1,373 individuals with mild or asymptomatic infection, i.e. without pneumonia (hereafter referred to as “controls”). In total, 928 of the 3,503 patients were screened for the presence of auto-Abs to type I IFN [24,25] (Supplemental methods) and the 234 patients who tested positive were excluded from this analysis as they already have a major risk factor to develop critical COVID-19 [27]. In total, 1,301 of the 3,269 remaining patients had been included in previous studies restricted to a short list of 18 candidate genes [14,18] or to the X chromosome [28], and 1,968 had not been studied before. The mean age (SD) of the patients was 55.7 (17.4) years, with a male-to-female ratio of 2.4 (Table 1). The controls were significantly younger than the patients ($P < 0.0001$), with a mean age (SD) of 43.8 years (20.1 years) and were more likely to be female ($P < 0.0001$; male-to-female ratio = 0.7). The patients and controls were of various ethnic origins, mostly of

European and Middle Eastern ancestry, according to principal component analysis (PCA) (Figure 2). Raw sequencing data were either centralized in the HGID laboratory and processed with the HGID pipeline (2,492 cases and 870 controls) or processed separately by each sequencing hub (777 cases and 503 controls; See Supplemental Methods). A joint analysis was performed first on the combined sample of 3,269 patients and 1,373 controls. Given the heterogeneity of the cohort due to different ancestries and processing pipelines, we also performed a trans-ethnic and a trans-pipeline meta-analysis; only results consistent across the three analyses are reported here (See Supplemental Methods).

Genome-wide analysis under a co-dominant model

We first performed a GW rare variant burden analysis on the 3,269 patients with life-threatening COVID-19 and 1,373 controls with asymptomatic/mild COVID-19 under a co-dominant model, using nine sets of variants (See Supplemental Methods). The QQ plots for the joint analysis of the samples revealed no systematic deviations from the null hypothesis, and the genomic inflation factors (λ) were close to 1 (Supplemental Table 1). In total, 18,064 genes were analyzed with at least one of the nine variant sets, resulting in an effective number of independent tests (M_{eff}) for the joint analysis of 108,384, giving a Bonferroni-corrected significance threshold of 4.61×10^{-7} . No gene was found to be of GW significance (see the Manhattan plot in Figure 3A, Supplemental Table 2). The gene with the strongest association was *TREH*, encoding the trehalase enzyme, which hydrolyses trehalose, with rare (GnomAD allele frequency [AF] $< 10^{-4}$) non-synonymous variants associated with a lower risk of life-threatening COVID-19 (OR=0.12[95% CI 0.05-0.28], $P = 1.9 \times 10^{-6}$; Supplemental Table 3). In analyses of genes for which rare predicted loss-of-function (pLOF) variants were associated

with an increase in the risk of life-threatening COVID-19 (Table 2), the strongest association was that for *NPC2*, for rare (GnomAD AF < 0.01) pLOF variants, with 28 heterozygous carriers among patients (0.9%), and four heterozygous carriers (0.3%) among controls (OR = 5.41 [95% CI 1.8-16.4], $P = 5.8 \times 10^{-4}$). *NPC2* encodes the Niemann-Pick disease type C2 protein and homozygous LOF mutations of this gene cause Niemann-Pick disease [43]. *NPC2* interacts with *NPC1*, which is also an essential endosomal receptor for the Ebola virus [44,45]. Both *NPC1* and *NPC2* were implicated in the regulation of SARS-CoV-2 entry in a CRISPR screen[46]. Finally, we analyzed the 19 loci associated with critical pneumonia by GWAS [8,10,12]. None of them showed a significant association (Supplemental Table 4). The GW burden analysis under a dominant model yielded similar conclusions (Supplemental table 3).

Genome-wide analysis under a recessive model

We then performed a GW screen under a recessive model (autosomal and X-linked). In total, 4,511 genes were analyzed with at least one of the nine variant sets, resulting in 27,066 independent tests, giving a Bonferroni-corrected significance threshold of 1.85×10^{-6} . No gene reached GW significance (Figure 3B). In analyses of genes with rare variants increasing the risk of life-threatening COVID-19, *TLR7* was, by two orders of magnitude, the most significant gene, with 51 carriers (1.6%) of at least one rare (GnomAD AF < 0.01) missense or pLOF variant in patients versus two carriers (0.1%) in controls (OR = 8.41[95% CI 1.9-35.5], $P = 8.95 \times 10^{-5}$) (Table 3). Most of the carriers were male, with only one carrier among the patients and one among the controls being female. The variants carried by the two controls were previously shown to be biochemically neutral [18,28] (Supplemental table 5). The 51 cases carried 33 different variants, 13 of which had been shown to be neutral; 16 were previously

shown to be hypomorphic or amorphic [18,28], and four were previously unknown. The four new variants were tested: one was found to be neutral and the other three were deleterious (Supplemental Figure 1). Restricting the analysis to biochemically proven LOF variants (bLOF) decreased the number of carriers (20 cases vs. 0 controls), but the association signal remained highly significant, with a much higher odds ratio (OR = 27.68 [95% CI 1.5-528.7], $P = 1.08 \times 10^{-4}$) (Table 3). These findings confirm that *TLR7* is a critical COVID-19 susceptibility locus, responsible for 0.9% of critical cases in male patients.

Enrichment in rare pLOF variants at 13 type I IFN-related influenza susceptibility loci

Following on from our initial analysis [14], we also performed a candidate pathway enrichment analysis focusing on the 13 genes involved in Toll-like receptor 3 (TLR3)– and interferon regulatory factor 7 (IRF7)–dependent type I IFN immunity to influenza virus (*IFNAR1*, *IFNAR2*, *IRF3*, *IRF7*, *IRF9*, *IKBKG*, *STAT1*, *STAT2*, *TBK1*, *TICAM1*, *TLR3*, *TRAF3* and *UNC93B1*) (Figure 1). We confirmed the significant enrichment in rare (GnomAD AF < 10^{-3}) pLOF variants at the 13 loci in patients with critical COVID-19, with 34 carriers among patients versus six among controls (OR = 3.70 [95% CI 1.7-9.5], $P = 2.1 \times 10^{-4}$) under a co-dominant model; Table 4). We also estimated this p-value by a simulation study taking at random 13 loci over the whole genome (see supplemental methods). We found an empirical p-value of 2.5×10^{-4} . Excluding the 550 cases and 314 controls screened in a previous study [14] resulted in a similar conclusion (OR = 3.21 [95% CI 1.3-8.2], $P = 5.97 \times 10^{-3}$). Significant replication was also observed in the trans-ethnic ($P = 0.01$) and the trans-pipeline ($P = 0.009$) analyses. We found that 31 of the 34 carriers of pLOF variants were heterozygous, and three

were homozygous: one for a frameshift variant in *IRF7* described in a previous study [14], one for a previously reported deletion spanning 4,394 base pairs in *IFNARI* [15,18], and one for a previously unknown deletion spanning 6,624 base pairs of *IFNARI* (Supplemental Table 6). All the homozygous pLOF variants were found in patients. Consequently, the OR for homozygous carriers (OR = 15.79 [95%CI: 1.4-2170.4], $P = 0.02$) was higher than that for heterozygous carriers (OR = 3.11 [95%CI: 1.4-8.6], $P = 5.2 \times 10^{-3}$), but both were significant.

Rare pLOF variants of TYK2 and bLOF variants of TLR7

Since the publication of the aforementioned study [14], AR TYK2 deficiency has been reported in children with COVID-19 pneumonia [18]. We identified two patients, already described in another previous study [18], carrying a rare homozygous pLOF variant of *TYK2*, and one patient and one control carrying a rare heterozygous pLOF variant (Supplemental Table 6). Adding these patients to the analysis gave very similar results under a co-dominant model (OR = 3.30[95% CI 1.6-7.8], $P = 1.4 \times 10^{-4}$) and increased the evidence for association under a recessive model (OR = 19.65[95% CI 2.1-2635.4], $P = 3.4 \times 10^{-3}$) (Table 4). Analysis of the rare pLOF variants at these 14 loci plus the bLOF variants of *TLR7* revealed highly significant enrichment (OR = 3.82 [95%CI 2.0-7.2], $P = 1.3 \times 10^{-7}$ under a co-dominant model). The effect was stronger for homozygous/hemizygous carriers (OR = 39.19 [95%CI 5.2-5037.01], $P = 4.7 \times 10^{-7}$) than for heterozygous carriers (OR = 2.27 [95%CI 1.0-5.2], $P = 0.04$), and these two ORs were significantly different ($P = 0.008$). We also found that the 57 patients with critical COVID-19 carrying a rare pLOF or bLOF variant of one of these 15 genes were significantly younger than the remaining 3,212 patients in the cohort (mean age [SD] in years: 43.25 [20.3] vs. 56.0 [17.3] years; $P = 1.68 \times 10^{-5}$), consistent with our previous reports that IEs conferring

a predisposition to life-threatening COVID-19 are more frequent in young patients [1,14,28]. Moreover, homozygous/hemizygous carriers were significantly younger than heterozygous carriers (35.2 [20.3] vs. 49.5 [18.2] years, $P = 0.008$). Overall, these analyses indicate there is an enrichment in rare pLOF variants at 15 loci involved in type I IFN immunity in patients with critical COVID-19 pneumonia.

In-frame nonsynonymous variants at the 15 loci

We further screened our cohort for rare in-frame nonsynonymous variants with a GnomAD AF $< 10^{-3}$ at these type I IFN-related susceptibility loci. For the 13 initial loci, the enrichment disappeared when in-frame nonsynonymous variants were added to pLOF variants under a co-dominant model (OR = 1.08 [95%CI 0.9-1.3], $P = 0.42$) (Supplemental Table 7), whereas a non-significant trend persisted under the recessive model (OR = 5.02 [95% CI 0.7-52.7], $P = 0.06$). Focusing exclusively on in-frame variants decreased the strength of this trend considerably, with only eight homozygous carriers among patients and one among controls (OR = 1.14 [0.2-912.5], $P = 0.68$). Adding *TYK2* variants led to similar conclusions (Supplemental table 7). We then added *TLR7* variants and considered the 15 loci together. Under a co-dominant model, the enrichment became non-significant when in-frame nonsynonymous variants were added (OR = 1.15 [1.0-1.4], $P = 0.09$), but it remained significant under a recessive model (OR = 6.54[2.4-24.8], $P = 5.3 \times 10^{-6}$; Supplemental Table 7). In analyses considering only rare in-frame homozygous/hemizygous nonsynonymous variants, the effect size was smaller, but the enrichment remained significant (OR = 3.52[1.3-13.3], $P = 2.8 \times 10^{-3}$). In total, 41 patients carried a rare homozygous/hemizygous in-frame nonsynonymous variant in one of the 15 loci, and 16 of these variants (carried by 16 patients) were *TLR7* in-frame variants already shown to

be bLOF. After excluding the *TLR7* bLOF variants, there was no residual significant enrichment in rare in-frame nonsynonymous variants in patients relative to controls, whatever the genetic model considered.

Discussion

In this exome-wide gene burden analysis for rare variants underlying critical COVID-19, no gene reached GW statistical significance after accounting for multiple testing. These results are consistent with those of two previous large exome-wide studies including more than 1,000 critical cases and thousands of population-based controls that did not find statistically significant autosomal gene burden associations at stringent significance thresholds accounting for the number of phenotypes and variant sets analyzed [11,21]. However, under a recessive model, the strongest association - although not statistically significant at the GW level - was obtained with the X-linked *TLR7* gene, for which association has consistently been reported across studies [20,28,29], reaching the less conservative exome-wide significance threshold of 2.5×10^{-6} in some of these previous studies [20,21]. It should be stressed that stringent correction for multiple testing, while necessary to avoid false positives, is a conservative strategy, and that the lack of formal statistical significance at a GW level does not preclude biological causality and medical significance. The burden of proof can be provided experimentally via biochemical, virological, and immunological experiments, as we previously did for *TLR7* by showing that biochemically deleterious *TLR7* variants blunted the pDC-dependent sensing of SARS-CoV-2 and induction of type I IFN, thereby accounting for ~1% of critical pneumonia cases in men [28]. Additional genes may be found by restricting the association analysis to variants experimentally proven to be deleterious.

This analysis also confirms our previous findings of an enrichment in rare pLOF variants of 13 genes involved in TLR3- and IRF7-dependent type I IFN immunity to seasonal influenza virus in critical cases relative to controls with mild/asymptomatic infection [14]. These results were strengthened by the addition of *TYK2*, which was recently shown to underlie severe COVID-19 [18,19], and *TLR7*, especially under a recessive model. We found that homozygous/hemizygous carriers of rare pLOF or bLOF variants at the 15 loci had a significantly higher risk of life-threatening COVID-19 than heterozygotes. This is consistent with the generally higher clinical penetrance of recessive than dominant IEI [1]. Overall, 1.7% of the patients with life-threatening COVID-19 carried a rare pLOF or bLOF variant at one of the 15 loci, these variants being homozygous/hemizygous in 0.8%. The study of in-frame nonsynonymous variants might increase this proportion, but would require the experimental characterization of all these variants. Indeed, in analyses restricted to rare in-frame nonsynonymous variants, we detected no significant enrichment in patients relative to controls. This result is not surprising, as we showed in a previous study [14] that less than 15% of the rare in-frame nonsynonymous variants at the 13 initially studied loci carried by cases were bLOF variants, whereas all the pLOF variants were found to be bLOF. Similar results were obtained for *TLR7*, with only 10 of 108 (9.2%) in-frame nonsynonymous variants observed in GnomAD being bLOF [28]. This high proportion of neutral variants strongly affects the power of burden tests and highlights the need for the experimental characterization of variants.

We also showed that patients carrying rare pLOF or bLOF variants at these 15 type I IFN-related genes were significantly younger than the remaining patients (mean age [SD] in years: 43.3 [20.3] vs. 56.0 [17.3] years). This was particularly true for carriers of a homozygous/hemizygous rare pLOF or bLOF variant (35.2 [20.3] years), potentially accounting for the lack of replication of this finding by other studies including older patients

[11,20–22]. Consistent with this result, we recently found that ~10% of children hospitalized for COVID-19 pneumonia carry recessive inborn errors of type I IFN immunity [18]. In addition, older patients are more likely to carry auto-Abs against type I IFN, and contrary to other previous studies, we excluded patients carrying such antibodies from the analysis. None of the 234 patients with critical COVID-19 excluded from this study due to the presence of auto-Abs against type I IFN carried a rare pLOF variant of the 15 genes. Hence, samples in which the vast majority of patients are over the age of 60 years and of unknown status for auto-Abs against type I IFNs would have much reduced power to identify these rare inborn errors of type I IFN immunity. In conclusion, rare autosomal inborn errors of type I IFN-dependent immunity to influenza viruses can underlie critical forms of COVID-19, especially in subjects below 60 years of age, in addition to X-linked TLR7 deficiency. The search for additional rare mutations conferring a strong predisposition to life-threatening COVID-19 should focus on young patients with critical COVID-19 without auto-Abs against type I IFNs.

Declarations

Ethics approval and consent to participate

All the enrolled participants provided written informed consent for participation and were recruited through protocols conforming to local ethics requirements. For patients enrolled in the French COVID cohort (ClinicalTrials.gov NCT04262921), ethics approval was obtained from the Comité de Protection des Personnes Ile De France VI (ID RCB, 2020-A00256-33) or

the Ethics Committee of Erasme Hospital (P2020/203). For participants enrolled in the COV-Contact study (ClinicalTrials.gov NCT04259892), ethics approval was obtained from the CPP IDF VI (ID RCB, 2020-A00280-39). For patients enrolled in the Italian cohort, ethics approval was obtained from the University of Milano-Bicocca School of Medicine, San Gerardo Hospital, Monza–Ethics Committee of the National Institute of Infectious Diseases Lazzaro Spallanzani (84/2020) (Italy), and the Comitato Etico Provinciale (NP 4000–Studio CORONAlab). STORM-Health care workers were enrolled in the STudio OsseRvazionale sullo screening dei laboratori ospedalieri per COVID-19 (STORM-HCW) study, with approval from the local institutional review board (IRB) obtained on June 18, 2020. Patients and relatives from San Raffaele Hospital (Milan) were enrolled in COVID-BioB/Gene-COVID protocols and, for additional studies, TIGET-06, with the approval of the local ethics committee. Patients and relatives from Rome were enrolled in Protocol no. 50/20 (Tor Vergata University Hospital). Informed consent was obtained from each patient. For the patients enrolled in the COVIDeF Study Group (ClinicalTrials.gov NCT04352348), ethics approval was obtained from the Comité de Protection des Personnes Ile de France XI (ID RCB, 2020-A00754-35). For patients enrolled in Spain, the study was approved by the Committee for Ethical Research of the Infanta Leonor University Hospital, code 008-20; the Committee for Ethical Research of the 12 de Octubre University Hospital, code 16/368; the Bellvitge University Hospital, code PR127/20; the University Hospital of Gran Canaria Dr. Negrín, code 2020-200-1 COVID-19; and the Vall d’Hebron University Hospital, code PR(AMI)388/2016. Anonymized samples were sequenced at the National Institute of Allergy and Infectious Diseases (NIAID) through the Uniformed Services University of the Health Sciences (USUHS)/the American Genome Center (TAGC) under nonhuman subject research conditions; no additional IRB consent was required at the

National Institutes of Health (NIH). For patients enrolled in the Swedish COVID cohort, ethics approval was obtained from the Swedish Ethical Review Agency (2020-01911 05).

Data and materials availability

Data supporting the findings of this study are available within the manuscript and supplemental files. Patients were not consented to share the raw WES/WGS data files beyond the research and clinical teams. NIH patient data are available under dbGaP submission phs002245.v1.

Conflict of interest

The authors declare no competing financial interests. RN and AKK are employees of Invitae and hold equities in the company. RPL is a member of the board of directors of Roche and its subsidiary Genentech. I Meyts holds a chair in Primary Immunodeficiencies and receives research grant from CSL Behring, paid to KUL. JLC reported a patent to PCT/US2021/042741 pending. FT is head of the Centre de Pharmacoépidémiologie (Cephepi) of the Assistance Publique – Hôpitaux de Paris and of the Clinical Research Unit of Pitié-Salpêtrière hospital, both these structures have received unrestricted research funding and grants for the research projects handled and fees for consultant activities from a large number of pharmaceutical companies, that have contributed indiscriminately to the salaries of its employees. FT is not employed by these structures and did not receive any personal remuneration from these companies.

Author contributions

D Matuozzo, ET, AM, JM, YS, YZ, A Bolze, MC, BM, P Zhang, LA and AC performed computational analysis. D Matuozzo, AG, P Bastard, TA, LB, I Meyts, SYZ, A Puel, SBD, BB, EJ and QZ performed or supervised experiments, generated and analyzed data, and contributed to the manuscript by providing figures and tables. P Bastard, FB, HA, AAT, AA, IAD, LMA, RAA, AAA, GA, P Bergman, SB, YTB, IGB, OCM, SC, PC, GC, KC, RC, CAN, LEZ, CF, PKG, MG, FH, RH, SH, LH, NH, AK, SK, CK, RLL, JLF, D Mansouri, JMP, OMA, I Migeotte, PEM, GM, AMN, GN, AN, TO, FP, QPH, RP, LPS, DEP, CP, A Pujol, LFR, JGR, CRG, JR, PRQ, MS, A Sobh, PSP, YTL, IT, CT, JT, MZ, P Zawadzki, SZAM, HBF, MJB, SNC, MAC, CLD, JF, JRH, YLL, RPL, TM, THM, HVB, AL, MV, A Boland, JFD, FM, ST, GG, FT, PH, LDN and HCS evaluated and recruited patients and /or controls. CRG, A Schlüter, MS, MZ, P Zawadzki, SZAM, HBF, MJB, SNC, MAC, CLD, JF, JRH, YLL, RPL, TM, THM, HVB, AL, MV, A Boland, JFD, RN and AKK performed sequencing. D Matuozzo, BB, JLC, QZ, LA and AC wrote the manuscript. JLC, QZ, LA and AC supervised the project. All the authors edited the manuscript and approved its final version.

Acknowledgements and fundings

We thank the patients and their families for agreeing to participate in our research. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George

Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the "Investments for the Future" program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union's Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l'enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. The study was supported by the ORCHESTRA project, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 10101616. P Bastard was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health, Fondation AP-HP et

Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). H.C.S is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G.N. and A.N. are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. I Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959). This work is supported by the Swiss National Science Foundation (grant # 310030L_197721 to JF). This work is supported by ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, and COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grant AJF202059 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I Erkizia, E Grau, M Massanella, and J Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling and processing. See Supplemental Acknowledgments for the list of consortia members.

References

1. Zhang Q, Bastard P, COVID Human Genetic Effort, Cobat A, Casanova J-L. Human genetic and immunological determinants of critical COVID-19 pneumonia. *Nature*. 2022;603:587–98.
2. COVID-19 Forecasting Team. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. *The Lancet*. Elsevier; 2022;399:1469–88.
3. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. Nature Publishing Group; 2021;590:140–5.
4. Bennett TD, Moffitt RA, Hajagos JG, Amor B, Anand A, Bissell MM, et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. *JAMA Netw Open*. 2021;4:e2116901.
5. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature*. Nature Publishing Group; 2020;588:315–20.
6. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. *Nature*. 2021;600:472–7.
7. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. *J Clin Invest* [Internet]. American Society for Clinical Investigation; 2021 [cited 2022 Apr 29];131. Available from: <https://www.jci.org/articles/view/152386>
8. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. *Nature*. Nature Publishing Group; 2021;591:92–8.
9. Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. *Nature*. 2020;587:610–2.
10. Pathak GA, Karjalainen J, Stevens C, Neale BM, Daly M, Ganna A, et al. A first update on mapping the human genetic architecture of COVID-19. *Nature*. Nature Publishing Group; 2022;608:E1–10.
11. Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, et al. Whole genome sequencing reveals host factors underlying critical Covid-19. *Nature*. Nature Publishing Group; 2022;1–10.

12. Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. *Nature*. Nature Publishing Group; 2022;1–6.
13. Zeberg H, Pääbo S. A genomic region associated with protection against severe COVID-19 is inherited from Neandertals. *Proc Natl Acad Sci U S A*. 2021;118:e2026309118.
14. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*. 2020;370:eabd4570.
15. Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du L, et al. Inherited IFNAR1 Deficiency in a Child with Both Critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome. *J Clin Immunol*. 2022;42:471–83.
16. Khanmohammadi S, Rezaei N, Khazaei M, Shirvani A. A Case of Autosomal Recessive Interferon Alpha/Beta Receptor Alpha Chain (IFNAR1) Deficiency with Severe COVID-19. *J Clin Immunol*. 2022;42:19–24.
17. Schmidt A, Peters S, Knaus A, Sabir H, Hamsen F, Maj C, et al. TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. *NPJ Genomic Med*. 2021;6:55.
18. Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T, et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. *J Exp Med*. 2022;219:e20220131.
19. Ogishi M, Arias A, Yang R, Han JE, Zhang P, Rinchai D, et al. Impaired IL-23–dependent induction of IFN- γ underlies mycobacterial disease in patients with inherited TYK2 deficiency. *J Exp Med - Press*. 2022;
20. Butler-Laporte G, Povysil G, Kosmicki J, Cirulli ET, Drivas T, Furini S, et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative [Internet]. medRxiv; 2022 [cited 2022 Apr 29]. p. 2022.03.28.22273040. Available from: <https://www.medrxiv.org/content/10.1101/2022.03.28.22273040v1>
21. Kosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, et al. Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. *Am J Hum Genet*. 2021;108:1350–5.
22. Povysil G, Butler-Laporte G, Shang N, Wang C, Khan A, Alaamery M, et al. Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. *J Clin Invest* [Internet]. American Society for Clinical Investigation; 2021 [cited 2022 Apr 29];131. Available from: <https://www.jci.org/articles/view/147834>
23. Zhang Q, Cobat A, Bastard P, Notarangelo LD, Su HC, Abel L, et al. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-

- 19 pneumonia. *J Clin Invest* [Internet]. American Society for Clinical Investigation; 2021 [cited 2022 Apr 29];131. Available from: <https://www.jci.org/articles/view/152474>
24. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* [Internet]. American Association for the Advancement of Science; 2020 [cited 2021 Feb 3];370. Available from: <https://science.sciencemag.org/content/370/6515/eabd4585>
25. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. *Sci Immunol*. 2021;6:eabl4340.
26. Casanova J-L, Abel L. From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. *Cell*. 2022;185:3086–103.
27. Manry J, Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. *Proc Natl Acad Sci. Proceedings of the National Academy of Sciences*; 2022;119:e2200413119.
28. Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Maglorius Renkilaraj MRL, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. *Sci Immunol*. American Association for the Advancement of Science; 2021;6:eabl4348.
29. Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. van de Veerdonk FL, van der Meer JW, editors. *eLife*. eLife Sciences Publications, Ltd; 2021;10:e67569.
30. Mantovani S, Daga S, Fallerini C, Baldassarri M, Benetti E, Picchiotti N, et al. Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. *Genes Immun*. 2022;23:51–6.
31. Pessoa NL, Bentes AA, de Carvalho AL, de Souza Silva TB, Alves PA, de Sousa Reis EV, et al. Case report: hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism. *Virology*. 2021;18:180.
32. Solanich X, Vargas-Parra G, van der Made CI, Simons A, Schuurs-Hoeijmakers J, Antoli A, et al. Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. *Front Immunol*. 2021;12:719115.
33. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19. *JAMA*. 2020;324:663–73.
34. van der Made CI, Netea MG, van der Veerdonk FL, Hoischen A. Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. *Genome Med*. 2022;14:96.

35. Brown GJ, Cañete PF, Wang H, Medhavy A, Bones J, Roco JA, et al. TLR7 gain-of-function genetic variation causes human lupus. *Nature*. Nature Publishing Group; 2022;605:349–56.
36. Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. *Nat Rev Genet*. 2010;11:17–30.
37. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am J Hum Genet*. 2007;81:559–75.
38. Belkadi A, Pedergnana V, Cobat A, Itan Y, Vincent QB, Abhyankar A, et al. Whole-exome sequencing to analyze population structure, parental inbreeding, and familial linkage. *Proc Natl Acad Sci U S A*. 2016;113:6713–8.
39. Firth D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika*. [Oxford University Press, Biometrika Trust]; 1993;80:27–38.
40. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinforma Oxf Engl*. 2010;26:2190–1.
41. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology*. 2012;143:1244-1252.e12.
42. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. *Heredity*. Nature Publishing Group; 2005;95:221–7.
43. Verot L, Chikh K, Freydière E, Honoré R, Vanier MT, Millat G. Niemann-Pick C disease: functional characterization of three NPC2 mutations and clinical and molecular update on patients with NPC2. *Clin Genet*. 2007;71:320–30.
44. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. *Nature*. 2011;477:340–3.
45. Zhao Y, Ren J, Harlos K, Stuart DI. Structure of glycosylated NPC1 luminal domain C reveals insights into NPC2 and Ebola virus interactions. *FEBS Lett*. 2016;590:605–12.
46. Zhu Y, Feng F, Hu G, Wang Y, Yu Y, Zhu Y, et al. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. *Nat Commun*. Nature Publishing Group; 2021;12:961.
47. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res*. 2019;47:D886–94.
48. Itan Y, Shang L, Boisson B, Ciancanelli MJ, Markle JG, Martinez-Barricarte R, et al. The mutation significance cutoff: gene-level thresholds for variant predictions. *Nat Methods*. 2016;13:109–10.

Figure legends

Figure 1. Type I IFN immunity genes associated with life-threatening COVID-19

Inborn errors of type I IFN immunity and autoantibodies neutralizing type I IFNs (α , β , ω) underlie life-threatening COVID-19 pneumonia by interfering with type I IFN immunity in respiratory epithelial cells (RECs) and blood plasmacytoid dendritic cells (pDCs). SARS-CoV-2 infection can induce type I IFN production in a TLR3-dependent manner in tissue-resident RECs (which express TLR3 but not TLR7) and in a TLR7-dependent manner in circulating pDCs (which express TLR7 but not TLR3). IRF7 is constitutively expressed in pDCs, at higher levels than in other cell types, whereas it is mostly induced by viral infection in RECs. Reported in red are the 13 genes (*IFNAR1*, *IFNAR2*, *IRF3*, *IRF7*, *IRF9*, *IKBKG*, *STAT1*, *STAT2*, *TBK1*, *TICAM1*, *TLR3*, *TRAF3* and *UNC93B1*) investigated in a previous study [14]; *TYK2* and *TLR7* were subsequently shown to underlie severe COVID-19 [18,28].

Figure 2. Principal component analysis of patients with life-threatening COVID-19 (red) and controls with asymptomatic or mild infection (green).

Principal component analysis (PCA) was performed with PLINK v1.9 software [37] on a pruned subset of ~14,600 exonic SNPs in linkage equilibrium (maximum r^2 value for linkage disequilibrium of 0.4 between pairs of SNPs) with a minor allele frequency (MAF) > 1%, call-rate > 99% and P value for departure from Hardy-Weinberg equilibrium > 10^{-5} . Samples were of diverse ethnic origins, including European (EUR), admixed American (AMR), North-African (NAFR), sub-Saharan African (AFR), Middle Eastern (ME), South Asian (SAS) and East Asian (EAS).

Figure 3. Manhattan plot for the genome-wide burden analysis under the co-dominant (A) and recessive (B) models.

The red lines represent the significance threshold after Bonferroni correction accounting for the total number of independent tests ($P = 4.61 \times 10^{-7}$ under a co-dominant model and 1.85×10^{-6} under a recessive model).

Table 1 – Baseline characteristics of study participants

	Life-threatening COVID-19	Infected controls	P value^a
	<i>n = 3269</i>	<i>n = 1373</i>	
Sex, no. (%)			
Male	2314 (70.8%)	542 (39.5%)	<0.0001
Female	955 (29.2%)	831 (60.5%)	
Age (years)			
Mean (SD)	55.74 (17.40)	43.83 (20.14)	<0.0001
Median (range)	57 (0.08-99)	43 (0.08-105)	
Processing pipeline, no. (%)			
HGID laboratory ^b	2492 (76.2%)	870 (63.4%)	<0.0001
Other	777 (24.8%)	503 (36.6%)	
Ancestry, no. (%)			
European	1374 (42.0%)	960 (69.9%)	<0.0001
Middle Eastern	483 (14.8%)	158 (11.5%)	
Admixed American	466 (14.3%)	109 (7.9%)	
North African	300 (9.2%)	24 (1.7%)	
South Asian	279 (8.5%)	36 (2.6%)	
Sub-Saharan African	234 (7.1%)	43 (3.1%)	
East Asian	133 (4.1%)	43 (3.1%)	

^a Chi-squared tests were used to compare proportions, and *t* tests were used to compare the mean ages.

^bHGID: Human Genetics of Infectious Diseases

Table 2. Top results of the genome-wide burden analysis for rare pLOF variants increasing the risk of life-threatening COVID-19 under a co-dominant model.

Chr	Gene	GnomAD AF threshold	No. carriers of at least one (no. homozygous) pLOF variant		Joint analysis		Trans-ethnic meta-analysis	Trans-pipeline meta-analysis
			Cases (<i>n</i> =3269)	Controls (<i>n</i> =1373)	OR[95%CI]	<i>P</i> value	<i>P</i> value	<i>P</i> value
14	<i>NPC2</i>	0.01	28 (0)	4 (0)	5.41[1.8-16.4]	5.8x10 ⁻⁴	2.1x10 ⁻³	3.3x10 ⁻⁴
3	<i>DLECI</i>	0.01	56 (0)	16 (0)	2.55[1.3-4.9]	3.6x10 ⁻³	0.013	4.9x10 ⁻³
13	<i>NEK5</i>	0.001	16 (0)	0 (0)	27.03[0.9-864.2]	4.0x10 ⁻³	1.5x10 ⁻³	0.011
5	<i>CCNI2</i>	0.01	19 (1)	1 (0)	7.15[1.2-43.1]	4.1x10 ⁻³	4.1x10 ⁻³	5.0x10 ⁻³
22	<i>C22orf29</i>	0.001	13 (0)	0 (0)	15.6[0.8-315.8]	4.5x10 ⁻³	7.9x10 ⁻³	4.6x10 ⁻³
20	<i>DLGAP4</i>	0.001	37 (0)	3 (0)	4.35[1.3-14.5]	4.8x10 ⁻³	8.3x10 ⁻³	0.011

AF: allele frequency

Only genes with a *P* value $\leq 5 \times 10^{-3}$ in the joint analysis and *P* values < 0.05 in trans-ethnic and trans-pipeline meta-analyses are displayed.

Table 3. Top results of the genome-wide burden analysis for rare variants increasing the risk of life-threatening COVID-19 under a recessive model.

Chr	Gene	Variant set	CADD > MSC ^a	GnomAD AF threshold	No. carriers of at least one rare		Joint analysis		Trans-ethnic	Trans-pipeline
					homo-/hemizygous variant		OR[95%CI]	P value	meta-analysis	meta-analysis
					Cases (n=3269)	Controls (n=1373)			P value	P value
<i>GW analysis</i>										
X	<i>TLR7</i>	MISSLOF	FALSE	0.01	51	2	8.41 [1.9-35.5]	8.95x10 ⁻⁵	7.04x10 ⁻⁴	2.66x10 ⁻⁴
14	<i>AHNAK2</i>	MISSLOF	TRUE	0.001	37	2	4.45 [1.1-17.7]	0.01	2.15x10 ⁻³	8.84x10 ⁻³
<i>Refined analysis on TLR7</i>										
X	<i>TLR7</i>	bLOF	-	0.01	20	0	27.68[1.5-528.7]	1.1x10 ⁻⁴	6.6x10 ⁻³	2.7x10 ⁻⁴

AF: allele frequency

Only genes with P values ≤ 0.01 in the joint analysis and P values < 0.05 in trans-ethnic and trans-pipeline meta-analyses are displayed.

^a Combined Annotation Dependent Depletion (CADD) score [47] greater than the Mutation Significance Cut-off (MSC) for the corresponding gene. The MSC is defined for a given gene as the lower limit of the confidence interval (95%) of the CADD score of all its known pathogenic mutations [48].

Table 4. Enrichment in pLOF/bLOF rare variants of genes involved in type I IFN immunity

Gene set	Cohort	Model	No. carriers		Joint analysis		Trans-pipeline	Trans-ethnic
			Cases	Controls	P value	OR[95%CI]	meta-analysis	meta-analysis
							P value	P value
13 genes ^a	Samples independent of [14] ^b	Co-dominant	25	5	5.97x10 ⁻³	3.21[1.3-8.2]	9.15x10 ⁻³	0.01
13 genes	Full ^c	Co-dominant	34	6	2.13x10 ⁻⁴	3.70[1.7-9.5]	7.45x10 ⁻⁴	6.52x10 ⁻⁴
13 genes	Full	Heterozygous only ^d	31	6	5.21x10 ⁻³	3.11[1.3-8.6]	7.88x10 ⁻³	5.98x10 ⁻³
13 genes	Full	Recessive	3	0	0.02	15.79[1.4-2170.4]	0.05	0.03
13 genes + <i>TYK2</i>	Full	Co-dominant	37	7	1.40x10 ⁻⁴	3.30[1.6-7.8]	5.77x10 ⁻⁴	5.64x10 ⁻⁴
13 genes + <i>TYK2</i>	Full	Heterozygous only	32	7	0.02	2.53[1.1-6.6]	0.03	0.02

13 genes + <i>TYK2</i>	Full	Recessive	5	0	3.36×10^{-3}	19.65 [2.1-2635.4]	9.84×10^{-3}	0.03
13 genes + <i>TYK2</i> + bLOF <i>TLR7</i>	Full	Co-dominant	57	9	1.27×10^{-7}	3.82 [2.0-7.2]	1.99×10^{-7}	2.20×10^{-6}
13genes + <i>TYK2</i> + bLOF <i>TLR7</i>	Full	Heterozygous only	32	9	0.04	2.27[1.0-5.2]	0.04	0.02
13genes + <i>TYK2</i> + bLOF <i>TLR7</i>	Full	Recessive	25	0	4.69×10^{-7}	39.19[5.2-5037.01]	2.39×10^{-6}	6.66×10^{-5}

^a*IFNAR1, IFNAR2, IRF3, IRF7, IRF9, IKBKG, STAT1, STAT2, TBK1, TICAM1, TLR3, TRAF3 and UNC93B1*

^b2719 patients and 1059 controls newly recruited and not screened in [14]

^cThe full cohort includes 3269 patients and 1373 controls

^dIn this model, only subjects with heterozygous variants are considered as carriers

Figure 1




Figure 2





Figure 3

A – Co-dominant model



B – Recessive model

